

Amendment to the Claims. Please amend claims 1, 15, 16, 18, 19 and 22-31 and cancel claims 2-14, 17, 20 and 21 without prejudice as set forth below.

Listing of the claims. This listing replaces any previous listing.

1 (Currently amended). A method for treating an inflammatory response in the gastrointestinal tract of a subject by modulating physiology or development of a macrophage cell expressing a receptor for a TECK polypeptide, which polypeptide comprises ~~comprising~~ the amino acid sequence set forth in Gln1 to Leu127 of SEQ ID NO: 4, comprising contacting the cell with ~~an agonist or~~ an antagonist antibody or an antigen-binding fragment thereof that binds specifically to ~~of~~ the polypeptide.

2-14 (Cancelled).

15 (Currently amended). The method of Claim ~~1~~ 1 wherein the inflammatory response is in the colon of the subject.

16 (Currently amended). The method of Claim ~~1~~ 1 wherein the inflammatory response is in the small intestine of the subject.

17 (Cancelled).

18 (Currently amended). The method of Claim ~~17~~ 1 wherein the gastrointestinal inflammation is Crohn's disease.

19 (Currently amended). The method of Claim ~~17~~ 1 wherein the gastrointestinal inflammation is inflammatory bowel disease.

20-21 (Cancelled).

22 (Currently amended). The method of Claim ~~21~~ 1 wherein the ~~binding composition~~ antibody or antigen-binding fragment is conjugated to a chemical moiety.

23 (Currently amended). The method of Claim ~~21~~ 1 wherein the ~~binding composition~~ antigen-binding fragment is a Fv fragment.

24 (Currently amended). The method of Claim ~~21~~ 1 wherein the ~~binding composition~~ antigen-binding fragment is a Fab fragment.

25 (Currently amended). The method of Claim ~~21~~ 1 wherein the ~~binding composition~~ antigen-binding fragment is a Fab2 fragment.

26 (Currently amended). The method of Claim ~~21~~ 1 wherein the ~~binding composition~~ antibody is a monoclonal antibody.

27 (Currently amended). The method of Claim ~~21~~ 1 wherein the ~~binding composition~~ antibody is a polyclonal antibody.

28 (Currently amended). The method of Claim ~~21~~ 1 wherein the ~~binding composition~~ antibody or antigen-binding fragment exhibits a Kd greater than 300 μM to the TECK polypeptide.

29 (Currently amended). The method of Claim ~~21~~ 1 wherein the ~~binding composition~~ antibody or antigen-binding fragment exhibits a Kd greater than 30 μM to the TECK polypeptide.

30 (Currently amended). The method of Claim ~~21~~ 1 wherein the ~~binding composition~~ antibody or antigen-binding fragment exhibits a Kd greater than 10 μM to the TECK polypeptide.

31 (Currently amended). The method of Claim ~~21~~ 1 wherein the ~~binding composition~~ antibody or antigen-binding fragment exhibits a Kd greater than 3 μM to the TECK polypeptide.